Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More
Pfizer India is a 71% subsidiary of the world's largest pharmaceuticals company Pfizer Inc. Pfizer derives a larger share of its revenues from the pharmaceuticals division (81%). The company also has presence in the animal health (13%) and clinical d... More
DIVIS LABORATORIES | PFIZER | DIVIS LABORATORIES/ PFIZER |
|||
---|---|---|---|---|---|
P/E (TTM) | x | 57.8 | 43.2 | 133.7% | View Chart |
P/BV | x | 13.3 | 7.1 | 186.3% | View Chart |
Dividend Yield | % | 0.5 | 0.5 | 96.0% |
![]() ![]() |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
DIVIS LABORATORIES Mar-19 |
PFIZER Mar-19 |
DIVIS LABORATORIES/ PFIZER |
5-Yr Chart Click to enlarge
|
||
High | Rs | 1,639 | 3,840 | 42.7% | |
Low | Rs | 1,115 | 2,080 | 53.6% | |
Sales per share (Unadj.) | Rs | 186.3 | 455.0 | 41.0% | |
Earnings per share (Unadj.) | Rs | 51.0 | 93.8 | 54.3% | |
Cash flow per share (Unadj.) | Rs | 57.3 | 109.4 | 52.4% | |
Dividends per share (Unadj.) | Rs | 16.00 | 22.50 | 71.1% | |
Dividend yield (eoy) | % | 1.2 | 0.8 | 152.8% | |
Book value per share (Unadj.) | Rs | 261.8 | 658.2 | 39.8% | |
Shares outstanding (eoy) | m | 265.47 | 45.75 | 580.3% | |
Bonus/Rights/Conversions | - | - | - | ||
Price / Sales ratio | x | 7.4 | 6.5 | 113.6% | |
Avg P/E ratio | x | 27.0 | 31.6 | 85.6% | |
P/CF ratio (eoy) | x | 24.0 | 27.1 | 88.8% | |
Price / Book Value ratio | x | 5.3 | 4.5 | 117.0% | |
Dividend payout | % | 31.4 | 24.0 | 130.9% | |
Avg Mkt Cap | Rs m | 365,592 | 135,420 | 270.0% | |
No. of employees | `000 | 11.8 | 2.6 | 450.3% | |
Total wages/salary | Rs m | 5,423 | 3,238 | 167.4% | |
Avg. sales/employee | Rs Th | 4,175.1 | 7,911.4 | 52.8% | |
Avg. wages/employee | Rs Th | 457.7 | 1,230.9 | 37.2% | |
Avg. net profit/employee | Rs Th | 1,141.8 | 1,630.7 | 70.0% |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 49,463 | 20,815 | 237.6% | |
Other income | Rs m | 1,556 | 1,674 | 93.0% | |
Total revenues | Rs m | 51,019 | 22,489 | 226.9% | |
Gross profit | Rs m | 18,718 | 5,712 | 327.7% | |
Depreciation | Rs m | 1,689 | 714 | 236.6% | |
Interest | Rs m | 35 | 73 | 48.0% | |
Profit before tax | Rs m | 18,551 | 6,599 | 281.1% | |
Minority Interest | Rs m | 0 | 0 | - | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 5,023 | 2,309 | 217.6% | |
Profit after tax | Rs m | 13,527 | 4,291 | 315.3% | |
Gross profit margin | % | 37.8 | 27.4 | 137.9% | |
Effective tax rate | % | 27.1 | 35.0 | 77.4% | |
Net profit margin | % | 27.3 | 20.6 | 132.7% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 46,501 | 27,167 | 171.2% | |
Current liabilities | Rs m | 8,468 | 8,917 | 95.0% | |
Net working cap to sales | % | 76.9 | 87.7 | 87.7% | |
Current ratio | x | 5.5 | 3.0 | 180.3% | |
Inventory Days | Days | 131 | 68 | 192.9% | |
Debtors Days | Days | 86 | 30 | 285.2% | |
Net fixed assets | Rs m | 25,797 | 8,862 | 291.1% | |
Share capital | Rs m | 531 | 458 | 116.0% | |
"Free" reserves | Rs m | 68,962 | 29,656 | 232.5% | |
Net worth | Rs m | 69,493 | 30,113 | 230.8% | |
Long term debt | Rs m | 0 | 25 | 0.0% | |
Total assets | Rs m | 80,383 | 39,400 | 204.0% | |
Interest coverage | x | 531.0 | 91.5 | 580.2% | |
Debt to equity ratio | x | 0 | 0 | 0.0% | |
Sales to assets ratio | x | 0.6 | 0.5 | 116.5% | |
Return on assets | % | 16.9 | 11.1 | 152.4% | |
Return on equity | % | 19.5 | 14.2 | 136.6% | |
Return on capital | % | 26.7 | 22.1 | 120.8% | |
Exports to sales | % | 0 | 0 | - | |
Imports to sales | % | 24.6 | 0 | - | |
Exports (fob) | Rs m | NA | NA | - | |
Imports (cif) | Rs m | 12,187 | NA | - | |
Fx inflow | Rs m | 41,238 | 428 | 9,628.2% | |
Fx outflow | Rs m | 12,405 | 786 | 1,577.5% | |
Net fx | Rs m | 28,833 | -358 | -8,051.5% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 9,543 | 978 | 975.7% | |
From Investments | Rs m | -6,854 | 351 | -1,951.6% | |
From Financial Activity | Rs m | -2,459 | -1,099 | 223.9% | |
Net Cashflow | Rs m | 230 | 231 | 99.5% |
Indian Promoters | % | 52.0 | 0.0 | - | |
Foreign collaborators | % | 0.0 | 63.9 | - | |
Indian inst/Mut Fund | % | 11.8 | 7.5 | 157.3% | |
FIIs | % | 19.0 | 4.9 | 387.8% | |
ADR/GDR | % | 0.0 | 0.0 | - | |
Free float | % | 17.2 | 23.7 | 72.6% | |
Shareholders | 31,796 | 85,207 | 37.3% | ||
Pledged promoter(s) holding | % | 0.0 | 0.0 | - |
Compare DIVIS LABORATORIES With: PIRAMAL ENTERPRISES ABBOTT INDIA PANACEA BIOTECH DR. REDDYS LAB GSK PHARMA
Compare DIVIS LABORATORIES With: MYLAN (US) ACTAVIS (US) ADCOCK INGRAM (S. Africa) TEVA PHARMA (Israel)
Share markets in India are presently trading on a negative note. The BSE Sensex is trading down by 553 points, down 1.1% at 47,794 levels.
For the quarter ended September 2020, PFIZER has posted a net profit of Rs 1 bn (down 14.8% YoY). Sales on the other hand came in at Rs 6 bn (up 5.0% YoY). Read on for a complete analysis of PFIZER's quarterly results.
For the quarter ended June 2020, PFIZER has posted a net profit of Rs 1 bn (up 10.3% YoY). Sales on the other hand came in at Rs 5 bn (down 5.4% YoY). Read on for a complete analysis of PFIZER's quarterly results.
For the quarter ended June 2020, DIVIS LABORATORIES has posted a net profit of Rs 5 bn (up 84.1% YoY). Sales on the other hand came in at Rs 17 bn (up 50.0% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.
For the quarter ended March 2020, DIVIS LABORATORIES has posted a net profit of Rs 4 bn (up 35.4% YoY). Sales on the other hand came in at Rs 14 bn (up 9.5% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.
For the quarter ended December 2019, PFIZER has posted a net profit of Rs 1 bn (up 5.4% YoY). Sales on the other hand came in at Rs 5 bn (up 4.7% YoY). Read on for a complete analysis of PFIZER's quarterly results.
More Views on NewsIn this video, I'll show you why it might be the right time to take money of the table in pharma stocks.
The pandemic failed to thwart Richa's investing success formula for 2020.
In this video, I'll show you a crucial chart that you need to check before you decide to sell any stock or index.
Our ace stock picker is ready to capitalise on a big growth opportunity.
More